BEGIN:VCALENDAR
VERSION:2.0
PRODID: -//Q4 Inc.//EN
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
ORGANIZER:MAILTO:investors@innate-pharma.fr
DTSTART;TZID="America/New_York":20261118T110000
DTEND;TZID="America/New_York":20261118T120000
LOCATION:IET London, Savoy Place, 2 Savoy Place, London WC2R 0BL, United Kingdom
UID:988aa4ca-4c81-473f-b2dc-3747fc8c2273
DTSTAMP:20261106T033943
SUMMARY:Innate Pharma in-person and virtual event focused on IPH4502: IPH4502 Phase 1 clinical data and development outlook
DESCRIPTION: View More Information: https://investors.innate-pharma.com/English/investors/events-and-presentations/events/event-details/2026/Innate-Pharma-in-person-and-virtual-event-focused-on-IPH4502-IPH4502-Phase-1-clinical-data-and-development-outlook/default.aspx
URL;VALUE=URI:https://investors.innate-pharma.com/English/investors/events-and-presentations/events/event-details/2026/Innate-Pharma-in-person-and-virtual-event-focused-on-IPH4502-IPH4502-Phase-1-clinical-data-and-development-outlook/default.aspx
PRIORITY:5
CLASS:PUBLIC
END:VEVENT
END:VCALENDAR